Clarus Medical

Focus: Clarus Medical is a newly founded (2024) biotechnology company headquartered in Minneapolis focused on endocrinology therapies, specifically developing oral testosterone formulations for hypogonadism treatment.

Endocrinology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Clarus Medical

AI assessmentNot Hiring

No open roles listed right now. Follow Clarus Medical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Oral testosterone undecanoate

Hypogonadism

Phase 2

Clinical Trials (1)

NCT00695110Pharmacokinetic Study of Oral Testosterone (T) Ester Formulations in Hypogonadal Men

Phase 2

Help build intelligence for Clarus Medical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a newly launched company with focused pipeline in endocrinology, a large underserved market
Lead program (oral testosterone undecanoate) is in Phase 3 with near-term regulatory catalysts
Early-stage environment enables rapid skill acquisition and potential equity upside before scale

Watch Out For

Company is pre-revenue with no disclosed funding, creating significant financial uncertainty and burn-rate risk
Currently zero open positions advertised, suggesting either stealth-mode hiring or limited near-term headcount expansion
Extremely limited public information on management team, financing, or operational status raises execution risk

Generated by Claude from Clarus Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Testosterone undecanoate

Hypogonadism

Phase 2

Clinical Trials (1)

NCT02697188Pilot Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men

Phase 2

Oral testosterone undecanoate

Male Hypogonadism

Phase 3

Clinical Trials (1)

NCT01403116Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2024

Portfolio: 3 clinical trials

Top TAs: Endocrinology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Endocrinology

3 pipeline

Marketed

Pipeline